Background
Malignant pleural mesothelioma (PM) is a highly aggressive thoracic malignancy with an extremely poor prognosis and limited effective therapeutic strategies, representing a critical unmet clinical need. Fanconi anemia complementation group D2 (FANCD2) is a critical effector of the cellular DNA damage respons...
Ying-Fang Xiang, Pu Su, Rui-Ying Zhang et al.· Frontiers in Genetics· 0 citations
Malignant tumors remain a leading cause of global mortality, and the development of chemoresistance represents a major obstacle to effective cancer treatment. Long non-coding RNAs (lncRNAs) are important regulators of tumor progression and therapeutic response. Cancer susceptibility candidate 2 (CASC2) is an lncRNA tha...
Ling-Yun Zhou, Jin-Tao He, Wen-Bing Huang et al.· Journal of chemotherapy· 0 citations
GAS6-AS1 represents a promising molecule for understanding cancer pathogenesis and developing novel strategies for precision cancer diagnosis and treatment, although further clinical validation and mechanistic studies are still required.
Zhi-Ling Lu, Wen-Bing Huang, Jin-Tao He et al.· Biomedical Reports· 0 citations
Pleural mesothelioma (PM) is a highly aggressive asbestos-related malignancy with poor prognosis and limited early diagnostic options. In this study, network toxicology and integrated multi-omics analyses were used to investigate the molecular mechanisms by which chrysotile, crocidolite, and amosite may induce PM, and...
Shaoyang Huang, Dandan Gu, Jin-Tao He et al.· Chemico-Biological Interacti...· 0 citations
Preliminary mechanistic evidence is provided for further preclinical investigation of lycopene in PDAC, but its translational application will require optimized formulations, pharmacokinetic validation, and in vivo efficacy studies to overcome its limited bioavailability.
Shaoyang Huang, Dandan Gu, Dan Song et al.· Frontiers in Nutrition· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
